Erasca stock gains 4.12 percent ahead of trial data
Published on 09/25/2026 at 10:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Erasca stock gained 4.12 percent to USD 14.52 on Nasdaq on September 24, 2026, giving the clinical-stage biotechnology company a market capitalization of USD 5,040,284,040. The next major pipeline date is November 20, 2026, when updated ERAS-0015 data are scheduled for presentation.
ERAS-0015 data set for November
According to Erasca, updated monotherapy data from the Phase 1 AURORAS-1 trial of ERAS-0015 will be presented orally at the EORTC-NCI-AACR symposium from November 18 to 20, 2026. The company also plans a poster presentation covering nonclinical combination data for ERAS-0015 and ERAS-4001.
The oral presentation is scheduled for November 20, 2026, and will include additional patients and longer follow-up. Earlier dose-escalation results included confirmed partial responses at doses as low as 8 mg once daily, while the combination program targets KRAS G12X-driven models.
Quarterly loss missed consensus
Erasca reported a second-quarter 2026 loss of USD 0.14 per share, compared with a consensus loss of USD 0.11. The USD 0.03 shortfall was reported by MarketBeat in September 2026.
The same quarter produced a net loss of USD 44.1 million, compared with USD 33.9 million a year earlier. Research and development spending rose to USD 35.9 million from USD 21.2 million, while cash stood at USD 384.3 million on June 30, 2026, according to Inside Monkey.
Stock remains below yearly high
Erasca traded at USD 14.52 on Nasdaq on September 24, 2026, against a 52-week range of USD 1.79 to USD 24.28. The current price was 40.2 percent below the yearly high, while the 4.12 percent daily gain placed the November clinical update ahead of the next major disclosed milestone.
Erasca stock key facts
- Company: Erasca, Inc.
- Ticker: ERAS
- Trading venue: Nasdaq
- Price as of September 24, 2026: USD 14.52
- Market capitalization: USD 5,040,284,040 as of September 24, 2026
- 52-week range: USD 1.79-24.28 as of September 24, 2026
- Sector / Industry: Healthcare / Biotechnology
